Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with ...

Discover the effectiveness and safety of Mounjaro, the new weight loss drug launched in India. Learn from expert Dr. Pal ...

A once-weekly dose of tirzepatide (Mounjaro) can lead to significant, sustained weight loss for up to 3 years in adults with ...

Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, ...

New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that around ...